IL10 and myeloid sarcoma: Based on the observation that increased production of IL-10 by CD4+ T cells and B cells after helminth infection induced modulation of EAE and MS, it seems reasonable to postulate recombinant IL-10 use (rIL-10) for MS patient treatment.